UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

Journal of vascular surgery, 2006-04, Vol.43 (4), p.742-751.e1

2006

Volltextzugriff (PDF)

Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial

Journal of vascular surgery, 2005-09, Vol.42 (3), p.456-464

2005

Volltextzugriff (PDF)

Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients

Hepatology (Baltimore, Md.), 2003-12, Vol.38 (6), p.1419-1427, Article ajhep09040

2003

Volltextzugriff (PDF)

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age

Vaccine, 2013-11, Vol.31 (46), p.5300-5305

2013

Volltextzugriff (PDF)

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood, 2023-11, Vol.142 (Supplement 1), p.3479-3479

2023

Volltextzugriff (PDF)

OTO-201 for the Treatment of Acute Otitis Externa: Results from a Phase 3 Randomized Clinical Study

Annals of otology, rhinology & laryngology, 2019-06, Vol.128 (6), p.524-533

2019

Volltextzugriff (PDF)

Abstract CT107: Phase I/II safety and pharmacokinetics of BION-1301 targeting APRIL, a proliferation-inducing ligand, in adults with relapsed or refractory multiple myeloma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT107-CT107

2019

Volltextzugriff (PDF)

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease

Vaccine, 2013-11, Vol.31 (46), p.5306-5313

2013

Volltextzugriff (PDF)

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

Blood, 2021-11, Vol.138 (Supplement 1), p.3858-3858

2021

Volltextzugriff (PDF)

OA-04 A Phase 1 Study of P-BCMA- ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S3-S3

2024

Volltextzugriff (PDF)

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Blood, 2020-11, Vol.136 (Supplement 1), p.29-30

2020

Volltextzugriff (PDF)

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Vaccine, 2012-03, Vol.30 (16), p.2689-2696

2012

Volltextzugriff (PDF)

Abstract CT071: Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT071-CT071

2024

Volltextzugriff (PDF)

Abstract CT070: Solid tumor patients require higher cyclophosphamide (cy) dose than multiple myeloma (MM) patients to achieve adequate lymphodepletion (LD) necessary to enable allogeneic CAR-T expansion

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT070-CT070

2024

Volltextzugriff (PDF)

728 Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers

Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A761-A761

2022

Volltextzugriff (PDF)

Comparison of Viral replication fitness of wild-type and lamivudine-resistant HBV in patients

Gastroenterology (New York, N.Y. 1943), 2003-04, Vol.124 (4), p.A709-A709

2003

Volltextzugriff (PDF)

Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients

Journal of hepatology, 2002-04, Vol.36, p.138-138

2002

Volltextzugriff (PDF)

Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection

Journal of hepatology, 2002-04, Vol.36, p.110-111

2002

Volltextzugriff (PDF)

Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre– and post–liver transplantation patients

Hepatology (Baltimore, Md.), 2003-12, Vol.38 (6), p.1419-1427

2003

Volltextzugriff (PDF)

On robustness of 2m × 3n fractional factorial resolution III designs against the unavailability of data

Computational statistics & data analysis, 1990-08, Vol.10 (1), p.11-16

1990

Volltextzugriff (PDF)

Risk factors, medical therapies and perioperative events in limb salvage surgery : Observations from the PREVENT III multicenter trial. Commentary

Journal of vascular surgery, 2005, Vol.42 (3), p.456-465

2005

Volltextzugriff (PDF)

On robustness of 2m x 3n fractional factorial resolution III designs against the unavailability of data

Computational statistics & data analysis, 1990, Vol.10 (1), p.11-16

1990

Volltextzugriff (PDF)

On robustness of 2 m × 3 n fractional factorial resolution III designs against the unavailability of data

Computational statistics & data analysis, 1990, Vol.10 (1), p.11-16

1990

Volltextzugriff (PDF)

Analysis of clinical data using neural nets

Journal of biopharmaceutical statistics, 1996, Vol.6 (1), p.83-104

1996

Volltextzugriff (PDF)

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. Commentary

Journal of vascular surgery, 2006, Vol.43 (4), p.742-751

2006

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Sprache

Englisch
(29)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(9)
Aged
(7)
Female
(7)
Life Sciences & Biomedicine
(7)
Male
(7)
Middle Aged
(7)
Science & Technology
(7)
Adult
(5)
Biological And Medical Sciences
(5)
Double-Blind Method
(5)
Medical Sciences
(5)
Adolescent
(3)
Allergy And Immunology
(3)
Hepatitis
(3)
Hepatitis B
(3)
Hepatitis B - Prevention & Control
(3)
Hepatitis B Surface Antigens - Immunology
(3)
Hepatitis B Vaccine
(3)
Hepatitis B Vaccines - Adverse Effects
(3)
Hepatitis B Vaccines - Immunology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial

Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

OTO-201 for the Treatment of Acute Otitis Externa: Results from a Phase 3 Randomized Clinical Study

Abstract CT107: Phase I/II safety and pharmacokinetics of BION-1301 targeting APRIL, a proliferation-inducing ligand, in adults with relapsed or refractory multiple myeloma

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

OA-04 A Phase 1 Study of P-BCMA- ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Abstract CT071: Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy

Abstract CT070: Solid tumor patients require higher cyclophosphamide (cy) dose than multiple myeloma (MM) patients to achieve adequate lymphodepletion (LD) necessary to enable allogeneic CAR-T expansion

728 Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers

Comparison of Viral replication fitness of wild-type and lamivudine-resistant HBV in patients

Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients

Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection

Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre– and post–liver transplantation patients

On robustness of 2m × 3n fractional factorial resolution III designs against the unavailability of data

Risk factors, medical therapies and perioperative events in limb salvage surgery : Observations from the PREVENT III multicenter trial. Commentary

On robustness of 2m x 3n fractional factorial resolution III designs against the unavailability of data

On robustness of 2 m × 3 n fractional factorial resolution III designs against the unavailability of data

Analysis of clinical data using neural nets

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. Commentary

Suchergebnisse filtern